Numaferm developed a platform technology for fast, scalable and cost-efficient production of peptides and proteins, with a focus on pepteins (PEPTides & protEINS) in the range of 30-500 amino acids. They serve customers from pharma, biotech, agriculture, and cosmetics offering peptides and proteins at highest qualities, within weeks, in a sustainable way. In this context partnership deals with global CDMO PolyPeptide and the world’s leading animal health company Zoetis were closed.
Founded in 2017 as a spin-out of Düsseldorf University, Numaferm has grown to over 20 staff.

Press releases

18. September 2017

Evonik is investing in NUMAFERM, a specialist in the biotechnological production of peptides

NUMAFERM makes the production of peptides more efficient Investment strengthens Evonik’s growth engines Health & Care and Specialty Additives at Evonik New technical applications are becoming realistic for the first time Through its Venture Capital unit, Evonik has invested in the start-up NUMAFERM and now holds a minority share in the spin-off of Heinrich Heine University Düsseldorf. The investment was made as part of a seed financing round and also includes investments by H
11. May 2017

NUMAFERM revolutionizes peptide production and receives seed financing

The Dusseldorf university spin-off NUMAFERM specializes in the biotechnical production of peptides and is able, through its newly developed platform technology, to dramatically reduce costs for this raw material. For the further technological development and an accelerated market entry, NUMAFERM GmbH is now receiving funding in the seven-digit range. High-Tech Gründerfonds (HTGF), Qiagen co-founders and European Business Angels Prof. Detlev Riesner and Dr. Jürgen Schumacher, as well as the Eur

Info & Contact

Dr. Christian Schwarz


Merowingerplatz 1a
40225 Düsseldorf

In portfolio

28. Apr 2017

Dr. Anke Caßing

Principal / Authorized Signatory